Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0
Hepatitis C virus (HCV) is an important etiologic agent for chronic liver diseases. Methods: The aim of this study was to evaluate the clinical usefulness of second-generation HCV core antigen assay by comparing the results of the assay with those of the COBAS AMPLICOR HCV MONITOR version 2.0 (COBAS...
Gespeichert in:
| Veröffentlicht in: | Liver international 2005-12, Vol.25 (6), p.1136-1141 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1141 |
|---|---|
| container_issue | 6 |
| container_start_page | 1136 |
| container_title | Liver international |
| container_volume | 25 |
| creator | Yokosuka, Osamu Kawai, Shigenobu Suzuki, Yoichi Fukai, Kenichi Imazeki, Fumio Kanda, Tatsuo Tada, Motohisa Mikata, Rintarou Hata, Akira Saisho, Hiromitsu |
| description | Hepatitis C virus (HCV) is an important etiologic agent for chronic liver diseases. Methods: The aim of this study was to evaluate the clinical usefulness of second-generation HCV core antigen assay by comparing the results of the assay with those of the COBAS AMPLICOR HCV MONITOR version 2.0 (COBAS v2.0). Results: HCV core antigen was detectable by this assay in 142-149 (95.3%) of serotype 1 (3821 plus or minus 322 fmol-l; mean plus or minus SD), in 56-58 (96.6%) of serotype 2 (2589 plus or minus 449 fmol-l), and in 6-6 (100%) of serotypes 1+2 (1240 plus or minus 548 fmol-l). The HCV core antigen levels measured by this assay correlated well with the HCV RNA levels by COBAS v2.0 (r=0.848, P |
| doi_str_mv | 10.1111/j.1478-3231.2005.01185.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_19422000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19422000</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_194220003</originalsourceid><addsrcrecordid>eNqNkE9PAjEQxRujifjnO8zJ29Z2l40sN2wwkIhrhHglzTKrJaXFnS3ih_G7WlA4O5d5-b335jCMgRRcxrldctm96yVZmkmeCpFzIWUv59sT1jkap0edZufsgmgphCyKXHbYt7LGmUpbmLZhYZD6MNxoG3RrvANfQ3XwA2EdrEOiHSasvFskb-iw-c2O1CtUvkHQrjWRgybSX_3IVmvdGIqRT9O-gyrvB1MYTJ4fx6p82dcm5dN4FvW-ARtsaHcw5eKKndXaEl7_7Ut28zCcqVGybvxHQGrnK0MVWqsd-kBzWXTT-ASR_Tv4A2P8Y8Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19422000</pqid></control><display><type>article</type><title>Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Yokosuka, Osamu ; Kawai, Shigenobu ; Suzuki, Yoichi ; Fukai, Kenichi ; Imazeki, Fumio ; Kanda, Tatsuo ; Tada, Motohisa ; Mikata, Rintarou ; Hata, Akira ; Saisho, Hiromitsu</creator><creatorcontrib>Yokosuka, Osamu ; Kawai, Shigenobu ; Suzuki, Yoichi ; Fukai, Kenichi ; Imazeki, Fumio ; Kanda, Tatsuo ; Tada, Motohisa ; Mikata, Rintarou ; Hata, Akira ; Saisho, Hiromitsu</creatorcontrib><description>Hepatitis C virus (HCV) is an important etiologic agent for chronic liver diseases. Methods: The aim of this study was to evaluate the clinical usefulness of second-generation HCV core antigen assay by comparing the results of the assay with those of the COBAS AMPLICOR HCV MONITOR version 2.0 (COBAS v2.0). Results: HCV core antigen was detectable by this assay in 142-149 (95.3%) of serotype 1 (3821 plus or minus 322 fmol-l; mean plus or minus SD), in 56-58 (96.6%) of serotype 2 (2589 plus or minus 449 fmol-l), and in 6-6 (100%) of serotypes 1+2 (1240 plus or minus 548 fmol-l). The HCV core antigen levels measured by this assay correlated well with the HCV RNA levels by COBAS v2.0 (r=0.848, P<0.0001). In relation to the outcome of interferon monotherapy, the pretreatment HCV core antigen levels of sustained and non-sustained virological responders were 659 plus or minus 189 and 4904 plus or minus 376 fmol-l in serotype 1, 1993 plus or minus 740 and 3145 plus or minus 519 fmol-l in serotype 2. The cutoff values with the best accuracy for HCV core Ag levels to discriminate between sustained and non-sustained virological response were 699 fmol-l for serotype 1 and 292 fmol-l for serotype 2, respectively, by receiver operating characteristic curve analysis. Conclusion: This new assay was considered to be useful in evaluating the HCV levels in patients with chronic hepatitis C.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/j.1478-3231.2005.01185.x</identifier><language>eng</language><subject>Hepatitis C virus</subject><ispartof>Liver international, 2005-12, Vol.25 (6), p.1136-1141</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Yokosuka, Osamu</creatorcontrib><creatorcontrib>Kawai, Shigenobu</creatorcontrib><creatorcontrib>Suzuki, Yoichi</creatorcontrib><creatorcontrib>Fukai, Kenichi</creatorcontrib><creatorcontrib>Imazeki, Fumio</creatorcontrib><creatorcontrib>Kanda, Tatsuo</creatorcontrib><creatorcontrib>Tada, Motohisa</creatorcontrib><creatorcontrib>Mikata, Rintarou</creatorcontrib><creatorcontrib>Hata, Akira</creatorcontrib><creatorcontrib>Saisho, Hiromitsu</creatorcontrib><title>Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0</title><title>Liver international</title><description>Hepatitis C virus (HCV) is an important etiologic agent for chronic liver diseases. Methods: The aim of this study was to evaluate the clinical usefulness of second-generation HCV core antigen assay by comparing the results of the assay with those of the COBAS AMPLICOR HCV MONITOR version 2.0 (COBAS v2.0). Results: HCV core antigen was detectable by this assay in 142-149 (95.3%) of serotype 1 (3821 plus or minus 322 fmol-l; mean plus or minus SD), in 56-58 (96.6%) of serotype 2 (2589 plus or minus 449 fmol-l), and in 6-6 (100%) of serotypes 1+2 (1240 plus or minus 548 fmol-l). The HCV core antigen levels measured by this assay correlated well with the HCV RNA levels by COBAS v2.0 (r=0.848, P<0.0001). In relation to the outcome of interferon monotherapy, the pretreatment HCV core antigen levels of sustained and non-sustained virological responders were 659 plus or minus 189 and 4904 plus or minus 376 fmol-l in serotype 1, 1993 plus or minus 740 and 3145 plus or minus 519 fmol-l in serotype 2. The cutoff values with the best accuracy for HCV core Ag levels to discriminate between sustained and non-sustained virological response were 699 fmol-l for serotype 1 and 292 fmol-l for serotype 2, respectively, by receiver operating characteristic curve analysis. Conclusion: This new assay was considered to be useful in evaluating the HCV levels in patients with chronic hepatitis C.</description><subject>Hepatitis C virus</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNqNkE9PAjEQxRujifjnO8zJ29Z2l40sN2wwkIhrhHglzTKrJaXFnS3ih_G7WlA4O5d5-b335jCMgRRcxrldctm96yVZmkmeCpFzIWUv59sT1jkap0edZufsgmgphCyKXHbYt7LGmUpbmLZhYZD6MNxoG3RrvANfQ3XwA2EdrEOiHSasvFskb-iw-c2O1CtUvkHQrjWRgybSX_3IVmvdGIqRT9O-gyrvB1MYTJ4fx6p82dcm5dN4FvW-ARtsaHcw5eKKndXaEl7_7Ut28zCcqVGybvxHQGrnK0MVWqsd-kBzWXTT-ASR_Tv4A2P8Y8Y</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Yokosuka, Osamu</creator><creator>Kawai, Shigenobu</creator><creator>Suzuki, Yoichi</creator><creator>Fukai, Kenichi</creator><creator>Imazeki, Fumio</creator><creator>Kanda, Tatsuo</creator><creator>Tada, Motohisa</creator><creator>Mikata, Rintarou</creator><creator>Hata, Akira</creator><creator>Saisho, Hiromitsu</creator><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20051201</creationdate><title>Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0</title><author>Yokosuka, Osamu ; Kawai, Shigenobu ; Suzuki, Yoichi ; Fukai, Kenichi ; Imazeki, Fumio ; Kanda, Tatsuo ; Tada, Motohisa ; Mikata, Rintarou ; Hata, Akira ; Saisho, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_194220003</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Hepatitis C virus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yokosuka, Osamu</creatorcontrib><creatorcontrib>Kawai, Shigenobu</creatorcontrib><creatorcontrib>Suzuki, Yoichi</creatorcontrib><creatorcontrib>Fukai, Kenichi</creatorcontrib><creatorcontrib>Imazeki, Fumio</creatorcontrib><creatorcontrib>Kanda, Tatsuo</creatorcontrib><creatorcontrib>Tada, Motohisa</creatorcontrib><creatorcontrib>Mikata, Rintarou</creatorcontrib><creatorcontrib>Hata, Akira</creatorcontrib><creatorcontrib>Saisho, Hiromitsu</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yokosuka, Osamu</au><au>Kawai, Shigenobu</au><au>Suzuki, Yoichi</au><au>Fukai, Kenichi</au><au>Imazeki, Fumio</au><au>Kanda, Tatsuo</au><au>Tada, Motohisa</au><au>Mikata, Rintarou</au><au>Hata, Akira</au><au>Saisho, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0</atitle><jtitle>Liver international</jtitle><date>2005-12-01</date><risdate>2005</risdate><volume>25</volume><issue>6</issue><spage>1136</spage><epage>1141</epage><pages>1136-1141</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Hepatitis C virus (HCV) is an important etiologic agent for chronic liver diseases. Methods: The aim of this study was to evaluate the clinical usefulness of second-generation HCV core antigen assay by comparing the results of the assay with those of the COBAS AMPLICOR HCV MONITOR version 2.0 (COBAS v2.0). Results: HCV core antigen was detectable by this assay in 142-149 (95.3%) of serotype 1 (3821 plus or minus 322 fmol-l; mean plus or minus SD), in 56-58 (96.6%) of serotype 2 (2589 plus or minus 449 fmol-l), and in 6-6 (100%) of serotypes 1+2 (1240 plus or minus 548 fmol-l). The HCV core antigen levels measured by this assay correlated well with the HCV RNA levels by COBAS v2.0 (r=0.848, P<0.0001). In relation to the outcome of interferon monotherapy, the pretreatment HCV core antigen levels of sustained and non-sustained virological responders were 659 plus or minus 189 and 4904 plus or minus 376 fmol-l in serotype 1, 1993 plus or minus 740 and 3145 plus or minus 519 fmol-l in serotype 2. The cutoff values with the best accuracy for HCV core Ag levels to discriminate between sustained and non-sustained virological response were 699 fmol-l for serotype 1 and 292 fmol-l for serotype 2, respectively, by receiver operating characteristic curve analysis. Conclusion: This new assay was considered to be useful in evaluating the HCV levels in patients with chronic hepatitis C.</abstract><doi>10.1111/j.1478-3231.2005.01185.x</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2005-12, Vol.25 (6), p.1136-1141 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19422000 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Hepatitis C virus |
| title | Clinical Studies: Evaluation of clinical usefulness of second-generation HCV core antigen assay: comparison with COBAS AMPLICOR HCV MONITOR assay version 2.0 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T21%3A26%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Studies:%20Evaluation%20of%20clinical%20usefulness%20of%20second-generation%20HCV%20core%20antigen%20assay:%20comparison%20with%20COBAS%20AMPLICOR%20HCV%20MONITOR%20assay%20version%202.0&rft.jtitle=Liver%20international&rft.au=Yokosuka,%20Osamu&rft.date=2005-12-01&rft.volume=25&rft.issue=6&rft.spage=1136&rft.epage=1141&rft.pages=1136-1141&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/j.1478-3231.2005.01185.x&rft_dat=%3Cproquest%3E19422000%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19422000&rft_id=info:pmid/&rfr_iscdi=true |